HHTM's mission is to bridge the knowledge gaps in treating hearing loss by providing timely information and lively insights to anyone who cares about hearing loss. Our contributors and readers are drawn from many sectors of the hearing field, including practitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them.
Featured image for “Bluetooth or T-Coil in Hearing Aids? For Now, We Need Both”
Oct. 14, 2022

Bluetooth or T-Coil in Hearing Aids? For Now, We Need Both

HHTM
Trick question. Bluetooth or T-coil: Which is more important to include in hearing aids? The answer, for now is both. Because they do different things. We use Bluetooth to stream via personal devices like laptops, smartphones and TV sets while T-coils let us tap into hearing loop systems in public spaces like theaters, conference and lecture halls, and even pharmacy check-out counters. (Learn more about
Featured image for “Complex Cochlear Implant Cases: Management and Troubleshooting”
Oct. 14, 2022

Complex Cochlear Implant Cases: Management and Troubleshooting

HHTM
SAN DIEGO, CALIFORNIA — Not all cochlear implant cases present in a traditional manner, which calls for audiologists to seek a second opinion in more intricate and difficult cases. Complex Cochlear Implant Cases: Management and Troubleshooting offers both new and experienced cochlear implant audiologists the opportunity to tap into the knowledge and experience of skilled colleagues who have handled unique
Featured image for “<strong>High School Student Creates Website Devoted to the Genetic Condition, TMPRSS3</strong>”
Oct. 14, 2022

High School Student Creates Website Devoted to the Genetic Condition, TMPRSS3

HHTM
A 15-year-old from Nebraska with cochlear implants and diagnosed at birth with hearing loss due to TMPRSS3 recently created a web resource devoted to TMPRSS3, the fifth most common gene causally associated with deafness.  For her efforts, Lily received the Girl Scout Gold Award, the highest honor a Girl Scout can receive. Her website, https://www.tmprss3.org, aims to help people with
Featured image for “Otonomy Clinical Results for OTO-413 Disappoint; No Meaningful Improvement Observed in Hearing Loss Patients”
Oct. 14, 2022

Otonomy Clinical Results for OTO-413 Disappoint; No Meaningful Improvement Observed in Hearing Loss Patients

HHTM
SAN DIEGO, CALIFORNIA — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests. These results are in
Featured image for “FDA Offers Clarification to States Regarding Final OTC Hearing Aid Rule”
Oct. 13, 2022

FDA Offers Clarification to States Regarding Final OTC Hearing Aid Rule

HHTM
WASHINGTON, D.C. — Today, the U.S. Food and Drug Administration (FDA) sent a letter to state officials offering clarifications about the Final Rule on OTC Hearing Aids, following requests by several professional organizations seeking to better understand the distinction between ‘Prescription’ and ‘OTC’ hearing aid categories. In part, the letter states, “We have received questions about some implications of these actions,
Featured image for “Synchrony Expands Partnership With Sycle to Deliver Integrated Digital Payments Solutions for Hearing Providers”
Oct. 13, 2022

Synchrony Expands Partnership With Sycle to Deliver Integrated Digital Payments Solutions for Hearing Providers

HHTM
STAMFORD, CT and DENVER, CO – Synchrony (NYSE: SYF), a leading consumer financing company, today announced the availability of Allegro Credit, a point of sale consumer financing solution for the hearing industry, on Sycle’s practice management platform. With the new integration, audiology providers can more quickly and easily deploy a comprehensive set of financing options – from a healthcare credit card
Featured image for “Rayovac Previews Latest Advancements at EUHA 2022”
Oct. 13, 2022

Rayovac Previews Latest Advancements at EUHA 2022

HHTM
It was another successful EUHA for RAYOVAC, a brand of battery manufacturer Energizer Holdings*, as it showcased its latest technology to hundreds of new delegates at the hearing industry’s largest annual event in Hannover, Germany.The company began shipping RAYOVAC® Sound Fusion™ Technology to the market this summer, in sizes 10, 13 and 312, with up to two-and-a-half days more battery
Featured image for “Sony Announces Launch of First OTC Hearing Aids in the US”
Oct. 12, 2022

Sony Announces Launch of First OTC Hearing Aids in the US

HHTM
SAN DIEGO, CALIFORNIA — Sony Electronics today announces the availability of its first over-the-counter (OTC) hearing aids for the U.S. market. Sony is re-imagining the hearing device space with a focus on innovation, accessibility and personalization. With the unique products, developed in partnership with WS Audiology, Sony aims to enhance the lives of consumers “by combining its unique premium technology, ultimate
Featured image for “Tuned and Soundly Announce Partnership”
Oct. 12, 2022

Tuned and Soundly Announce Partnership

HHTM
NEW YORK and LOS ANGELES — Tuned, a hearing health company focused on providing hearing care for all, and Soundly, the first-ever hearing health marketplace, today announced a partnership to bring medically-credentialed audiology consultation and advice to any consumer looking to purchase hearing aid products on Soundly. Tuned and Soundly will partner to create rich content experiences on Soundly.com and virtually match Soundly users with Tuned
Featured image for “Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss”
Oct. 12, 2022

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

HHTM
LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show